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The timing of puberty is highly variable and is associated with long-term health outcomes. To
date, understanding of the genetic control of puberty timing is based largely on studies in
women. Here, we report a multi-trait genome-wide association study for male puberty timing
with an effective sample size of 205,354 men. We find moderately strong genomic corre-
lation in puberty timing between sexes (rg= 0.68) and identify 76 independent signals for
male puberty timing. Implicated mechanisms include an unexpected link between puberty
timing and natural hair colour, possibly reflecting common effects of pituitary hormones on
puberty and pigmentation. Earlier male puberty timing is genetically correlated with several
adverse health outcomes and Mendelian randomization analyses show a genetic association
between male puberty timing and shorter lifespan. These findings highlight the relationships
between puberty timing and health outcomes, and demonstrate the value of genetic studies
of puberty timing in both sexes.
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The timing of puberty varies widely in populations and isdetermined by a broad range of environmental and geneticfactors1. Understanding the biological mechanisms
underlying such variation is an important step towards under-
standing why earlier puberty timing is consistently associated
with higher risks for a range of later life diseases, including several
cancers, cardiovascular disease and Type 2 diabetes2–4.
Most of our understanding of the genetic determinants of
puberty timing is based on studies in women, as the age of first
menstrual bleeding (age at menarche, AAM) is a well-recalled and
widely measured marker of female sexual development. A recent
large-scale genome-wide association study (GWAS) for AAM, in
∼370,000 women, identified 389 independent signals, accounting
for approximately one quarter of the estimated heritability for the
trait5. In contrast, genetic studies of puberty timing in men are
much fewer and smaller in scale, due to lack of data in many
studies on male pubertal milestones. We previously reported a
GWAS for recalled age at voice breaking in men (N= 55,871)
from a single study, 23andMe, which identified 14 genetic inde-
pendent genetic association signals, and many signals with similar
effect sizes on voice breaking as for AAM in women6. This
overlapping genetic architecture between puberty timing in males
(in 23andMe) and females was also reported by others7, and
supports the use of recalled age at voice breaking in men as an
informative measure of puberty timing for further genetic studies.
Although the overall shared genetic architecture for pubertal
timing between sexes is high (rg= 0.74) and many genetic var-
iants show similar effects sizes in both sexes, there are a number
of genetic signals that differ between sexes. Most notably, at the
SIM1/MCHR2 locus, the allele that promotes earlier puberty in
one sex delays it in the other6. Sex-specific expression patterns for
several of such highlighted genes was reported in the hypotha-
lamus and pituitary of pre-pubertal mice8. Further work to
identify the pubertal mechanisms that are divergent between
sexes may shed light on differences in later life disease risk
associations between sexes.
Here, we greatly extend our previously reported GWAS for age
at voice breaking in 23andMe6 by combining additional data
from the UK Biobank study9. In this four-fold larger sample, we
increase the number of genomic loci that have male-specific
effects on puberty timing from 5 to 29, and identify biological
pathways that warrant further investigation.
Results
Onset of facial hair as a marker of male puberty timing. Data
on relative age of voice breaking and relative age of first facial hair
were available in up to 207,126 male participants in the UK
Biobank (UKBB) study. For each of these measures, participants
were asked if the event occurred relative to their peers: younger
than average, about average or older than average. We previously
reported that signals for AAM in women show concordant
associations with dichotomised voice breaking traits in these
UKBB men5, but to our knowledge no genetic study has pre-
viously evaluated timing of facial hair appearance as a marker of
pubertal development.
We defined two dichotomous facial hair variables in UKBB
men: (1) relatively early onset (N= 13,226) vs. average onset
(N= 161,175); and (2) relatively late onset (N= 26,066) vs.
average onset. These facial hair traits were in concordance with
similarly dichotomised voice breaking traits defined in the same
individuals, although more men reported early or late facial hair
onset (39,292; 19.6%) than early or late voice breaking (19,579;
10.2%) (Supplementary Table 1). To test the ability of these facial
hair traits to detect puberty timing loci, we assessed their
associations with previously reported AAM loci. Of the 328
reported autosomal AAM signals for which genotype data were
available in UKBB, 266 (81.1%, binomial-P= 1.2 × 10−31) and
276 (84.1%, binomial-P= 2.1 × 10−38) showed directionally con-
cordant individual associations with relatively early and relatively
late facial hair, respectively. Furthermore, substantially more AAM
signals showed at least nominally significant associations (GWAS
P < 0.05) with relatively early (102, 31.1%) or relatively late facial
hair (152, 46.3%) compared to ~16 expected by chance for each
outcome (Supplementary Data 1).
A multi-trait GWAS for puberty timing in men. We analysed
four GWAS models in UKBB men (imputation v2, ~7.4M
SNPs): two models (early and late) for each of relative timing of
voice breaking and facial hair. The shared genetic architecture
between these four traits was high (genetic correlations (rg)
aligned to later timing of voice breaking ranged 0.57–0.91;
Supplementary Table 2), and all four showed high genetic cor-
relation with the continuously measured age at voice breaking in
23andMe (rg 0.61–0.81). These high correlations supported the
rationale to combine the GWAS data across all five strata using
MTAG10. This approach enables genetic data from correlated
traits and overlapping samples to be combined in a single
analysis, provided three key assumptions are met: (1) homo-
geneity of variance-covariance matrix for effect sizes for all
SNPs across all traits; (2) sampling variation can be ignored and
(3) sample overlap is adequately captured. Simulations involving
large numbers of traits with extreme sample overlap have
demonstrated that assumptions (2) and (3) may safely be made
for most applications of MTAG. Violation of the assumption of
homogeneity of effect sizes may be plausible in this setting if
some SNPs have an effect on voice breaking and not facial hair
(and vice-versa). We therefore calculated the upper bound for
the false discovery rate (FDR) in our meta-analysis using the
‘maxFDR’ calculation developed by the MTAG authors. As
the value for maxFDR was 7.9 × 10−4, this indicates that test
statistics are unlikely to be biased due to any violation of the
homogeneity assumption.
We therefore aimed to enhance power to identify GWAS
signals for continuous age at voice breaking (as recorded in
23andMe) by using MTAG to combine data from the four
dichotomous UKBB puberty timing traits all aligned to later
timing of voice breaking; this approach yielded an effective GWAS
meta-analysis sample size of 205,354 men for continuous pubertal
timing. In this combined MTAG dataset, we identified 7,897
variants associated with male puberty timing at the genome-wide
statistical significance threshold (GWAS-P < 5 × 10−8), compris-
ing 76 independent signals (Fig. 1; Supplementary Data 2). The
most significantly associated variant (rs11156429, GWAS-P=
3.5 × 10−52) was located in/near LIN28B, consistent with pre-
viously reported studies in men and women. Of these 76 signals,
29 were not in linkage disequilibrium (LD, conservatively defined
as r2 > 0.05) with a previously reported signal for puberty timing
(either AAM in women or voice breaking in men) (Table 1).
We sought collective confirmation of the 76 independent signals
for male puberty timing in up to 2394 boys with longitudinally
assessed pubertal sexual characteristics in The Avon Longitudinal
Study of Parents and Children (ALSPAC)11. In ALSPAC boys, a
polygenic risk score for later puberty timing based on 73 of the
male puberty timing signals was associated with older ages at voice
breaking, peak height velocity and appearance of armpit hair
(Linear regression: P= 4.5 × 10−3 to P= 1.6 × 10−14), and was
associated with lower likelihood of attaining various milestones of
pubertal maturation at specific time-points (Pmin (pubic hair
development at age 14.7 years old):= 4.6 × 10−10, univariate model
r2 ~ 1.5%)(Supplementary Data 3).
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Fig. 1 Miami plot of meta-analysis for age at voice breaking.Miami plot comparing –log10(P values) for SNP associations with age at voice breaking from
23andMe GWAS (bottom half, blue shades) with –log10(P values) from meta-analysis for age at voice breaking combining 23andMe data with UK Biobank
study (top half, red shades). Red line indicates genome-wide significance level (P < 5 × 10−8).
Table 1 Twenty nine previously unreported signals for puberty timing.
Variant Chr Position Alleles EAF Nearest gene Voice breaking
Beta (s.e.)a
Voice
breaking Pa
Menarche beta
(s.e.)b
Menarche Pb
rs71578952 7 131,001,466 C/T 0.495 MKLN1 0.035 (0.003) 8.4 × 10−28 0.000 (0.004) 0.94
rs2222746 17 44,222,019 T/G 0.165 KIAA1267 0.048 (0.004) 9.0 × 10−28 n/a n/a
rs73182377 3 181,512,034 C/T 0.227 SOX2OT 0.040 (0.004) 1.9 × 10−24 0.010 (0.005) 0.05
rs3824915 11 44,331,509 G/C 0.496 ALX4 0.030 (0.003) 1.0 × 10−20 0.008 (0.004) 0.05
rs77578010 1 11,035,758 A/G 0.776 C1orf127 0.036 (0.004) 1.1 × 10−20 0.006 (0.005) 0.18
rs7402990 15 28,384,491 G/A 0.916 HERC2 0.051 (0.006) 1.4 × 10−18 0.011 (0.008) 0.17
rs17833789 17 55,230,628 C/A 0.547 AKAP1 0.028 (0.003) 5.9 × 10−18 −0.001 (0.004) 0.83
rs12203592 6 396,321 C/T 0.170 IRF4 0.035 (0.004) 9.6 × 10−16 0.002 (0.006) 0.68
rs35063026 16 89,736,157 T/C 0.069 C16orf55 0.051 (0.006) 2.1 × 10−15 −0.007 (0.007) 0.34
rs9690350 7 547,800 C/G 0.419 PDGFA 0.025 (0.003) 3.2 × 10−14 −0.011 (0.008) 0.16
rs6560353 9 76,375,544 G/T 0.161 ANXA1 0.033 (0.004) 9.7 × 10−14 0.016 (0.005) 2.3 × 10−3
rs7905367 10 54,334,653 G/C 0.219 MBL2 0.027 (0.004) 4.7 × 10−12 −0.011 (0.005) 0.03
rs7136086 12 114,129,719 C/T 0.734 RBM19 0.025 (0.004) 1.4 × 10−11 0.019 (0.005) 3.2 × 10−5
rs10110581 8 60,691,207 G/A 0.263 CA8 0.025 (0.004) 2.3 × 10−11 0.014 (0.004) 1.3 × 10−3
rs2842385 6 19,078,274 G/A 0.193 MIR548A1 0.027 (0.004) 2.5 × 10−11 0.021 (0.005) 1.9 × 10−5
rs11836880 12 91,243,529 G/C 0.040 C12orf37 −0.053 (0.008) 1.1 × 10−10 0.006 (0.010) 0.55
rs10164550 2 121,159,205 A/G 0.657 INHBB 0.022 (0.003) 1.7 × 10−10 0.016 (0.004) 1.1 × 10−4
rs12895406 14 36,998,950 A/G 0.536 NKX2-1 0.021 (0.003) 2.8 × 10−10 0.007 (0.004) 0.05
rs835648 3 136,671,504 A/T 0.696 NCK1 0.022 (0.004) 5.2 × 10−10 0.006 (0.004) 0.20
rs780094 2 27,741,237 T/C 0.413 GCKR 0.020 (0.003) 7.8 × 10−10 0.018 (0.004) 3.7 × 10−6
rs1979835 5 135,689,839 A/G 0.876 TRPC7 0.029 (0.005) 2.5 × 10−9 0.024 (0.006) 2.7 × 10−5
rs12930815 16 4,348,635 C/T 0.521 TFAP4 0.019 (0.003) 2.6 × 10−9 0.008 (0.004) 0.03
rs12940636 17 53,400,110 C/T 0.655 HLF 0.020 (0.003) 3.6 × 10−9 0.023 (0.004) 1.4 × 10 –8(c)
rs60856990 17 7,337,853 A/G 0.629 TMEM102 0.019 (0.003) 1.3 × 10−8 −0.005 (0.004) 0.19
rs17193410 17 32,474,149 G/A 0.880 ACCN1 0.028 (0.005) 1.5 × 10−8 0.000 (0.007) 0.98
rs11761054 7 46,076,649 C/G 0.291 IGFBP3 −0.020 (0.004) 2.2 × 10−8 0.003 (0.004) 0.51
rs10765711 11 94,879,318 C/G 0.415 ENDOD1 0.018 (0.003) 2.9 × 10−8 −0.001 (0.004) 0.81
rs61168554 15 99,286,980 A/G 0.361 IGF1R 0.019 (0.003) 3.8 × 10−8 0.017 (0.004) 2.7 × 10−5
rs12983109 19 49,579,710 G/A 0.742 KCNA7 0.020 (0.004) 3.8 × 10−8 0.002 (0.005) 0.71
Alleles (effect/other), EAF effect allele frequency, Beta years per allele, s.e. standard error, P P-value from additive models.
aCurrent data from multi-trait GWAS for age at voice breaking in men.
bPreviously reported GWAS for age at menarche in women5.
cThis signal was not previously highlighted5 because that study used a distance-based metric to define independent signals rather than a LD based metric.
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Genetic heterogeneity between sexes. Consistent with our pre-
vious study6, we observed a moderately strong genome-wide
genetic correlation in pubertal timing between males and females
(rg= 0.68, P= 2.6 × 10−213; based on continuous data on voice
breaking and AAM in 23andMe), with similar effect estimates in
both sexes for many individual variants (Fig. 2). However, there
were exceptions to this overall trend: 5/76 male puberty timing
signals (Fig. 2b) and 15/387 reported AAM signals (Fig. 2a)
showed significant (by Bonferroni-corrected P values) hetero-
geneity between sexes in their effects on puberty timing (two of
these heterogeneous signals were found in both analyses) (Sup-
plementary Data 4 and 5; Fig. 2). Only one signal showed sig-
nificant directionally opposite effects (i.e. the allele that conferred
earlier puberty timing in one sex delayed puberty in the
other sex); rs6931884 at SIM1/PRDM13/MCHR2, as previously
reported (males: βvoice-breaking=−0.064 years/allele; females:
βmenarche= 0.059 years/allele; Pheterogeneity= 2.6 × 10−14). Two
variants located near to genes that are disrupted in rare disorders
of puberty12,13 showed no effect or weaker effect in males than
in females: rs184950120, 5′UTR to MKRN3 (βvoice-breaking=
0.085 years/allele; βmenarche= 0.396 years/allele, Pheterogeneity=
3.6 × 10−3), and rs62342064, one of 3 AAM variants in/near
TACR3 (βvoice-breaking=−0.017 years/allele; βmenarche= 0.057
years/allele, Pheterogeneity= 4.2 × 10−5).
Implicated genes, tissues and biological pathways. Two of the
76 lead variants associated with male pubertal timing were non-
synonymous: a previously reported AAM signal in KDM4C
(rs913588), encoding a lysine-specific demethylase, and a male-
specific signal in ALX4 (rs3824915), encoding a homeobox gene
involved in fibroblast growth factor (FGF) signalling that is
mutated in rare disorders of cranium/central neural system (CNS)
development with male-specific hypogonadism14. A further 10
lead variants were in strong LD (r2 > 0.8) with one or more non-
synonymous variants, of which three have not previously been
associated with puberty timing: FGF11, which encodes a FGF
expressed in the developing CNS and promotes peripheral
androgen receptor expression15, TFAP4, which encodes a tran-
scription factor of the basic helix-loop-helix-zipper family16, and
GCKR, which encodes a regulatory protein that inhibits glucoki-
nase in liver and pancreatic islets and is associated with a range of
cardiometabolic traits17 (Supplementary Table 3). A further seven
are reported signals for AAM, but were not previously reported for
voice-breaking. These missense variants are in the following genes:
SRD5A2, encoding for Steroid 5-alpha-reductase, which converts
testosterone into the more potent androgen dihydrotestosterone;
LEPR, encoding the receptor for appetite and reproduction hor-
mone leptin; SMARCAD1, encoding a mediator of histone H3/H4
deacetylation; BDNF, FNDC9, FAM118A and ZNF446.
Consistent with genetic analyses of AAM in females, tissues in
the CNS were the most strongly enriched for genes co-located
near to male puberty timing associated variants (Supplementary
Figs. 1 and 2; Supplementary Data 6 and Supplementary Table 4).
To identify mechanisms that regulate pubertal timing in males,
we tested all SNPs genome-wide for enrichment of voice breaking
associations with pre-defined biological pathway genes. Four
pathways showed evidence of enrichment: histone methyltrans-
ferase complex (FDR= 0.01); regulation of transcription (FDR=
0.02)); ATP binding (FDR= 0.03); and cAMP biosynthetic
process (FDR= 0.03) (Supplementary Data 7).
Links between hair colour and puberty timing. Noting that
three loci for puberty timing were located proximal to genes
previously associated with pigmentation (HERC2, IRF4, C16orf55),
we assessed the broader relationship between these traits. It is
known that men have darker natural hair colour than women in
European ancestry populations18 and this sex difference appears
following the progressive darkening of hair and skin colour during
adolescence19,20. However, a link between inter-individual varia-
tion in natural hair colour and puberty timing has not previously
been described. We assessed this phenotypic relationship in up to
179,594 white males of European ancestry in UKBB in a model
including 40 genetic principal components (to adjust for even
minor subpopulation ethnic variations). Men with red, dark
brown and black natural hair colours showed progressively higher
odds of early puberty timing, relative to men with blond hair.
Similarly, women with darker natural hair colours had earlier
puberty timing relative to women with blond hair (Table 2).
To test the shared biological basis between these two phenotypes,
we systematically assessed the effects of genetic variants associated
with natural hair colour on puberty timing. Using a two-sample
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Fig. 2 Scatterplots comparing variants for effect size on age at menarche
and age at voice breaking. a Scatterplot for independent signals identified
in voice breaking meta-analysis (23andMe and UK Biobank) in MTAG.
X-axis depicts SNP effect on age at voice breaking in years from
23andMeGWAS; y-axis shows effect on AAM. b Scatterplot for known
AAM loci depicting effect size for menarche (x-axis) and age at voice
breaking (y-axis). Signals are colour-coded based on heterogeneity
P values.
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Mendelian randomisation (MR) approach, we modelled 119
recently reported GWAS hair colour signals as a single instrumental
variable18 on age at voice breaking (in 23andMe men). Such an
approach can provide more robust and explicit evidence that there
is shared biology between these two traits. The findings infer that
susceptibility to darker natural hair colour also confers earlier
puberty timing in men (βIVW=−0.044 years per ordered category,
PIVW= 7.10 × 10−3) with no evidence of heterogeneity across
signals (Cochrane Q: P= 0.99) or directional pleiotropy (MR-Egger
Intercept: P= 0.99) (Supplementary Fig. 3). Using a similar
approach in published AAM data in females5, we inferred a
directionally consistent but weaker association between darker
natural hair colour on earlier AAM (βIVW=−0.017, PIVW= 3.64 ×
10−3), and with modest heterogeneity across signals (Cochrane Q:
P= 0.038) (Supplementary Table 5).
Due to the partial overlapping samples between the SNP
instrument discovery and outcome in the above approach, we
performed a second, more conservative analysis, using a more
limited 5-SNP score aligned to darker hair colour in non-
overlapping data on white UK Biobank individuals, adjusting for
40 genetic principal components and geographical location of
testing centres. This found highly consistent results in men:
the 5-SNP score was associated with higher risk for early voice
breaking (PIVW= 1.72 × 10−19) and lower risk for late voice
breaking (PIVW= 5.90 × 10−6); but we found no association with
AAM in women (PIVW= 0.23) (Supplementary Table 5).
Male puberty timing and other complex traits and diseases. To
assess the extent of shared heritability between male puberty
timing and other complex traits, we calculated genome-wide
genetic correlations across 751 complex traits/datasets using LD
score regression21 (Supplementary Data 8). Apart from other
puberty and growth-related traits, the strongest positive genetic
correlation was observed with ‘overall health rating’, followed by
several social traits, including educational attainment, fluid
intelligence score and ages at first/last birth. Conversely, male
puberty timing showed negative genetic correlations with cardi-
ometabolic diseases, including Type 2 diabetes and hypertension,
as well as health risk behaviours, including alcohol intake fre-
quency and smoking (Supplementary Fig. 4). In general, early
genetically predicted puberty timing in men was correlated with
adverse health outcomes. We then performed MR analyses to test
the genetic association with two exemplar traits which have
previously been associated with puberty timing: lifespan22 and
prostate cancer5.
We previously reported genetic associations between earlier
AAM and higher risks for hormone sensitive cancers, when
adjusting for the protective effects of higher BMI5,23. Here, using a
similar two-sample multi-variate MR approach, we did not find a
significant association with prostate cancer (OR per year= 0.89,
95%CI= 0.79–1.01; PIVW= 0.06) or advanced prostate cancer (OR
per year= 0.82, 95%CI= 0.67–1.00; PIVW= 0.05) (Supplementary
Table 6; Supplementary Fig. 6). We used a similar MR approach to
test the relevance of male puberty timing genetics to lifespan (see
Methods). The findings support a genetic association between later
puberty timing in males and longer lifespan, corresponding to
9 months longer life per year later puberty (IVW P= 6.7 × 10−4)
(Fig. 3). The result was consistent after removal of one outlier
SNP (MR-PRESSO P= 8.3 × 10−4), and with methods robust to
the effects of heterogeneous SNPs (weighted median P= 0.02)
(Supplementary Table 7).
Discussion
Here, we report the a genetic study of male puberty timing by
performing a meta-analysis across closely related phenotypic
traits in two large studies. The effective sample size of 205,354
men is substantially higher than the previous GWAS in men (n=
55,871), although still smaller than similar studies in women (n∼
370,000). While there was overall moderately strong overlap
between sexes in the genetic architecture of puberty timing (rg=
0.68), several findings point to mechanisms with particular rele-
vance to men. The genes implicated in puberty timing include,
ALX4 and SRD5A2, the disruption of which leads to male
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Fig. 3 Effect of male puberty SNPs on longevity. Scatterplot of 73 male
puberty loci (pruned for heterogeneity) comparing effect sizes for puberty
timing (from MTAG) and longevity. Lines show results of different
Mendelian randomisation models: IVW (blue), weighted median (yellow).
Error bars indicate 95% confidence intervals for individual SNP
associations.
Table 2 Phenotypic associations between natural hair colour and puberty timing in UK Biobank men and women.
Natural hair colour Effecta in men 95% CI in men P-value in men Effecta in women 95% CI in women P-value in women
Blond (ref) (ref)
Red 1.17 1.02, 1.35 0.02 −0.100 −0.134, −0.066 6.2 × 10 −9
Light brown 1.00 0.91, 1.09 0.92 −0.026 −0.047, −0.005 0.01
Dark brown 1.45 1.34, 1.58 6.7 × 10 −18 −0.093 −0.114, −0.072 6.7 × 10 −18
Black 1.63 1.46, 1.81 1.2 × 10 −19 −0.059 −0.113, −0.005 0.03
CI confidence interval.
aEffect size in men (n= 179,549) is odds ratio for early relatively voice breaking (relative to blond hair). Effect size in women (n= 238,195) is mean difference in age at menarche in years (relative to
blond hair).
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pseudohermaphroditism whereas higher 5-alpha-reductase
activity has been reported in women with polycystic ovary syn-
drome24, and INHBB encoding the beta-B subunit of the hor-
mone Inhibin B, which is secreted by testicular Sertoli cells in
males. By contrast, the known female puberty timing locus at
INHBA, which encodes the beta-A subunit of the hormone
Inhibin A, showed little association with puberty timing in males.
Non-genetic observational studies have consistently reported
darkening of hair and skin pigmentation in children of European
ancestry during the peri-pubertal years19,20. Furthermore, the
established sexual dimorphism in pigmentation18 reportedly
appears from puberty onwards19 and the relatively darker skin
and hair of men compared to women is postulated to reflect the
stronger stimulation of melanogenesis by androgens compared to
estrogens25. Our findings suggest a more widespread overlap
between pigmentation and reproduction, possibly reflecting
common regulators of pituitary production of melanocortins and
gonadotrophins, or even an impact of melanocyte signalling on
puberty timing. The pituitary pro-peptide, pro-opiomelanocortin
(POMC), is cleaved into several peptides with significant mela-
nogenic activity (ACTH, α-MSH, and β-MSH) by the pro-
hormone convertase enzymes, PC-1 and PC-2, both of which are
implicated by previously reported loci for AAM in females5. The
relationship in women is more complicated suggesting that while
there is a relationship between pigmentation and puberty timing
in both sexes, it may act in a sex-specific manner.
Finally, our findings substantiate links between puberty timing
in men and later life health outcomes, including Type 2 diabetes
and hypertension. Our observed genetic association between
earlier puberty timing in males and reduced lifespan was con-
sistent across three different MR analytical approaches, which
reduces the likelihood of horizontal pleiotropy (where variants
influence lifespan though mechanisms separate to puberty tim-
ing). Plausible interpretations are a causal effect of earlier male
puberty timing on earlier mortality or widespread horizontal
pleiotropy (affecting >50% of variants for puberty timing)
whereby puberty variants affect biologic pathways, which on the
one hand determine puberty timing and on the other hand
influence the risk of mortality. We note that horizontal pleiotropy
may have been underestimated in this analysis as the same UK
Biobank population were included in both exposure and outcome
samples26. In conclusion, our findings demonstrate the utility of
multi-trait GWAS to combine data across studies with related
measures to provide insights into the regulation and con-
sequences of puberty timing.
Methods
23andMe study. Genome-wide SNP data were available in up to 55,871 men aged
18 or older of European ancestry from the 23andMe study. Age at voice breaking
was determined by response to the question ‘How old were you when your voice
began to crack/deepen?’ in an online questionnaire. Participants chose from one of
seven pre-defined age bins (under 9, 9–10 years old, 11–12 years old, 13–14 years
old, 15–16 years old, 17–18 years old, 19 years old or older). These were then re-
scaled to one year age bins post-analysis by a previously validated method27. SNPs
were excluded prior to imputation based on the following criteria: Hardy-Weinberg
equilibrium P < 10−20; call rate < 95%; or a large frequency discrepancy when
compared with European 1000 Genomes reference data6. Imputation of genotypes
was performed using the March 2012 ‘v3’ release of 1000 Genomes reference
haplotype panel. Genetic associations with puberty timing were obtained by linear
regression models using age and five genetically determined principal components
to account for population structure as covariates, with additive allelic effects
assumed. P values for SNP associations were computed using likelihood ratio tests.
Participants provided informed consent to take part in this research under a
protocol approved by Ethical and Independent Review Services, an institutional
review board accredited by the Association for the Accreditation of Human
Research Protection Programs.
UK Biobank. Genotyping for UK Biobank participants has been described in detail
previously9. For this analysis, we limited our sample to individuals of white
European ancestry. Age at voice breaking for male participants from the UK
Biobank cohort study was obtained by responses to the touchscreen question
‘When did your voice break?’ Participants were required to choose from one of five
possible options (younger than average, about average, older than average, do not
know, prefer not to answer). For age at first facial hair, respondents were asked to
choose from one of the same five options in response to the touchscreen question
‘When did you start to grow facial hair?’ In total, data were available in up to
191,270 individuals for voice breaking and 198,731 individuals for facial hair. UK
Biobank received ethical approval from the NHS National Research Ethics Service
North West (11/NW/0382).
Respondents who answered either ‘older than average’ or ‘younger than average’
were compared separately using the ‘about average’ group as a reference in a case-
control design for both phenotypes. For both voice breaking and facial hair,
relatively early and relatively late effect estimates were obtained using linear mixed
models which were applied using BOLT-LMM software, which accounts for cryptic
population structure and relatedness. Covariates included age, genotyping chip and
10 principle components.
Meta-analysis of voice breaking results. GWAS summary results for each of the
five strata (23andMe age at voice breaking; UK Biobank relatively early and late
voice breaking; and UK Biobank relatively early and late facial hair) all aligned to
later timing of voice breaking were meta-analysed using MTAG10. MTAG uses
GWAS summary statistics from multiple correlated traits to effectively increase
sample size and statistical power to detect genetic associations. Full details on the
methodology have been described previously10. In brief, MTAG estimates a
variance-covariance matrix to correlate the effect sizes of each trait using a
moments-based method, with each trait and genotype standardised to have a mean
of zero and variance of one. In addition, MTAG calculates a variance-covariance
matrix for the GWAS estimation error using LD score regressions. The effect
estimate for the association of each SNP on the trait of interest is then derived
using a moments-based function, in a generalisation of standard inverse-variance
weighted meta-analysis.
Prior to meta-analysis, we removed extremely rare variants (MAF < 0.01). In
addition, for the four UK Biobank strata we calculated the effective sample size using
Neff ¼
2
1
Ncases
þ 1Ncontrols
: ð1Þ
Effective sample sizes for early and late voice breaking were 15,711 and 21,217,
respectively, and 17,391 and 23,011 for early and late facial hair, respectively. We
used the genome-significant P-value threshold of P < 5 × 10−8 to determine
significant SNP associations. Independent signals were identified using distance-
based clumping, with the SNP with the lowest P-value within a 1 MB window being
considered the association signal at that locus.
Gene annotation and identification of loci. For each independent signal identi-
fied in the voice breaking meta-analysis, we identified all previously reported age at
menarche (AAM) and voice breaking (VB) loci within 1MB of that SNP. We
assessed if each locus had previously been associated with puberty timing (AAM or
VB) within 1MB, and if any such loci within 1MB were in LD (r2 < 0.05). Het-
erogeneity between AAM and VB for each SNP was determined by the I2 statistic
and P-value generated by the METAL software.
Gene annotation was performed using a combination of methods. Information
on the nearest annotated gene was obtained from HaploReg v4.1. In addition, other
genes in the region were identified using plots produced from LocusZoom. The
most likely causal variant was determined by combining this information with
identification of any non-synonymous variants within the region as well as
application of existing knowledge.
Replication in ALSPAC. The Avon Longitudinal Study of Parents and Children
(ALSPAC) recruited pregnant women resident in the Avon area of the UK with an
expected delivery date between 1 April 1991 and 31 December 1992. Since then,
mothers, partners, and offspring have been followed up regularly through ques-
tionnaires and clinical assessments11. The offspring cohort consists of 14,775 live-
born children (75.7% of the eligible live births). Full details of recruitment, follow-
up and data collection have been reported previously11. Ethical approval for the
study was obtained from the ALSPAC Ethics and Law committee and the Local
Research Ethics Committees. A series of nine postal questionnaires regarding
pubertal development was administered approximately annually from the time the
participant was aged 8 until he was aged 17. The questionnaires, which were
responded by either the parents or the participant, had schematic drawings and
verbal descriptions of secondary sexual characteristics (genitalia and pubic hair
development) based on the Tanner staging system, as well as information on
armpit hair growth and voice change. Age at voice change was considered the age
at which the adolescent reported his voice to be occasionally a lot lower or to have
changed completely. Weight and height were measured annually up to age 13 years,
then at ages 15 and 17 years by a trained research team. Age at peak height velocity
(PHV) was estimated using Superimposition by Translation And Rotation (SITAR)
mixed effects growth curve analysis28. The sample size available varied according to
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the phenotype, from 1126 (for genital development) to 2403 (for age at which
armpit hair started to grow).
The genetic risk score (GRS) was calculated based on 73 SNPs (genotypes at 3
SNPs were unavailable) weighted by the effect size reported for that SNP in the
ReproGen Consortium. The GRS was standardised, and results are presented as
increase in the phenotype per standard-deviation increase in the GRS. Linear
(continuous phenotype) and logistic (binary phenotype) regression analyses were
performed unadjusted and adjusted for age (except for age at PHV, age at voice
change and age at which armpit hair started to grow) and controlled for population
stratification using the first 10 principal components.
Gene expression and pathway analysis. We used MAGENTA to investigate
whether genetic associations in the meta-analysed dataset showed enrichment in
any known biological pathways. MAGENTA has previously been described in
detail29. In brief, genes are mapped to an index SNP based on a 150 kb window,
with a regression model applied to correct the P-value (gene score) for gene size,
SNP density and LD-related properties. Gene scores are ranked, and the numbers
of gene scores observed in a given pathway in the 75th and 95th percentiles are
calculated. A P-value for gene-set enrichment analysis (GSEA) is calculated by
comparing these values to one million randomly generated gene sets. Testing was
completed on 3216 pathways from four databases (PANTHER, KEGG, Gene
Ontology and Ingenuity). Significance was determined based on an FDR < 0.05 for
genes in the 75th or 95th percentile.
To determine tissue-specific expression of genes, we used information from the
GTEx project. GTEx characterises transcription levels of RNA in a variety of tissue
and cell types, using sample from over 1000 deceased individuals of European,
African-American and Asian descent. We investigated transcription levels of
significant genes identified in our meta-analysis of voice breaking in 53 different
tissue types. We used a conservative Bonferroni-corrected P-value of 9.4 × 10−4
(=0.05/53) to determine significance.
Association between hair colour and puberty timing. Information on natural
hair colour for UK Biobank participants was collected via touchscreen ques-
tionnaire, in response to the question ‘What best describes your natural hair col-
our? (If your hair colour is grey, the colour before you went grey)’. Participants
chose from one of 6 possible colours: blond, red, light brown, dark brown, black or
other. For our analyses, we restricted this to include only non-related individuals of
white European ancestry, totalling 190,845 men and 238,179 women. Hair colours
were assigned numerical values from lightest (blond) to darkest (black) in order to
perform ordered logistic regression of hair colour for both relative age at voice
breaking in men and AAM in women. In both cases, blond hair was used as the
reference group and models were adjusted for the top 10 principle components to
account for population structure. In men this produces an effect estimate as an
odds ratio for early puberty (relative to blond-haired individuals), while in women
the effect estimate is on a continuous scale for AAM (in years) relative to the mean
AAM for those with blond hair.
Genetic correlations. Genetic correlations (rg) were calculated between age of
puberty in males and 751 health-related traits which were publically available from
the LD Hub database using LD Score Regression21,30.
Mendelian randomisation analyses. GWAS summary statistics for longevity were
obtained from Timmers et al.31. Briefly, Timmers et al. performed a GWAS of
parent survivorship under the Cox proportional hazard model in 1,012,050 parent
lifespans of unrelated subjects using methods of Joshi et al.32, but extending UK
Biobank data to that of second release. Data were meta-analysed using inverse-
variance meta-analysis results from UK Biobank genomically British, Lifegen, UK
Biobank self-reported British (but not identified as genomically British), UK Bio-
bank Irish, and UK Biobank other white European descent. The resultant hazard
ratios and their standard errors were then taken forward for two-sample MR using
the 74 male puberty loci which were available in both datasets. We then performed
a sensitivity analysis after removing outlier SNPs on the basis of heterogeneity
using MR-PRESSO33.
Summary statistics for the association between the genetic variants and risk of
prostate cancer were obtained from the PRACTICAL/ELLIPSE consortium, based
on GWAS analyses of 65,044 prostate cancer cases and 48,344 controls (all of
European ancestry) genotyped using the iCOGS or OncoArray chips34. The
analyses were repeated using summary statistics from a comparison of the subset of
9,640 cases with advanced disease versus 45,704 controls, where advanced cases
were defined as those with at least one of: Gleason score 8+, prostate cancer death,
metastatic disease or PSA > 100. Two-sample MR analyses were conducted using
weighted linear regressions of the SNP-prostate cancer log odds ratios (logOR) on
the SNP-puberty beta coefficients, using the variance of the logORs as weights. This
is equivalent to an inverse-variance weighted meta-analysis of the variant-specific
causal estimates. Because of evidence of over-dispersion (i.e. heterogeneity in the
variant-specific causal estimates), the residual standard error was estimated,
making this equivalent to a random-effects meta-analysis. Unbalanced horizontal
pleiotropy was tested based on the significance of the intercept term in MR-Egger
regression. The total effect of puberty timing on prostate cancer risk was separated
into a direct effect (independent of BMI, a potential mediator) and an indirect
effect (operating via BMI), as described in Burgess et al.19.
Genetic associations between hair colour and puberty timing were assessed in two
ways. First, we performed a two-sample MR analysis based on summary statistics (as
described in Burgess et al.19) using the most recently reported GWAS for hair
colour18 and 23andMe data for SNP effect estimates on age at voice breaking in men,
and published ReproGen consortium data on AAM in women. However, there is
partial overlap (between samples used for the discovery phase GWAS of hair colour
variants (n= 290,891 from 23andMe plus UK Biobank) and the samples used for
puberty timing (n= 55,871 men from 23andMe; maximum potential overlap=
55,871/290,891= 19%). Therefore, we also performed a sensitivity analysis in non-
overlapping samples; we used a more limited 5-SNP instrument for darker hair colour
(identified in an earlier hair colour GWAS that did not include UK Biobank35), and
assessed its effects on puberty timing in UK Biobank men and women in an
individual-level MR analysis, controlling for geographical (assessment centre) and
genetic ancestry factors (40 principal components).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Puberty associations: The results for the top 10000 SNPs detailed in this manuscript can be
found at this https://doi.org/10.17863/CAM.46703. UK Biobank: Data are available to all
bona fide researchers for all types of health-related research that is in the public interest,
without preferential or exclusive access for any person. All researchers, whether in
universities, charities, government agencies or commercial companies, and whether based
in the UK or abroad, will be subject to the same application process and approval criteria.
23andMe: Full summary statistics for 23andMe datasets will be made available to qualified
researchers under an agreement that protects participant privacy. Researchers should visit
https://research.23andme.com/dataset-access/ for more details and instructions for
applying for access to the data. ALSPAC: Please note that the study website contains details
of all the data that is available through a fully searchable data dictionary and variable
search tool at http://www.bristol.ac.uk/alspac/researchers/our-data/.
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